Randomized Trial of Glutathione with Anti-PD-1 and Chemotherapy in Advanced NSCLC
Launched by THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY · Mar 20, 2025
Trial Information
Current as of April 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a substance called glutathione can make current treatments for advanced non-small cell lung cancer (NSCLC) more effective. NSCLC is a common type of lung cancer, and the study aims to see if adding glutathione to standard chemotherapy and immunotherapy (which helps the immune system fight cancer) can improve treatment outcomes. Researchers believe that glutathione might help boost the immune response against the cancer, potentially leading to better patient survival.
To participate in this trial, you need to be at least 18 years old and have been diagnosed with either lung squamous cell carcinoma or adenocarcinoma. You should also have experienced disease progression after your first round of chemotherapy or chemo-immunotherapy. However, patients with other types of lung cancer, those who have stopped treatment, or women who are pregnant or breastfeeding cannot join the study. If you are eligible, you can expect to receive treatment and monitoring as part of the trial to help researchers understand how well glutathione works in combination with existing therapies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Histologically or cytologically confirmed diagnosis of lung squamous cell carcinoma or adenocarcinoma.
- • 2. Documented disease progression following first-line chemotherapy or chemo-immunotherapy.
- • 3. Age ≥18 years at the time of enrollment.
- Exclusion Criteria:
- • 1. Patients with small cell lung cancer or other histological subtypes of lung cancer.
- • 2. Patients lost to follow-up, who discontinued treatment, or died within one year of diagnosis.
- • 3. Pregnant or lactating women
About The First Affiliated Hospital Of Zhengzhou University
The First Affiliated Hospital of Zhengzhou University is a leading medical institution dedicated to advancing healthcare through innovative clinical research. As a prominent teaching hospital, it combines cutting-edge medical practices with a commitment to patient-centered care. The hospital is recognized for its comprehensive array of specialties and its collaborative approach to research, fostering partnerships with academic and healthcare organizations. By engaging in rigorous clinical trials, the hospital aims to contribute to the development of new therapies and improve treatment outcomes, ultimately enhancing the quality of care for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported